Synergistic bacterial compositions and methods of production and use thereof
Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
1. A composition comprising: (a) a first species of an isolated bacterium capable of forming a spore, (b) a second species of isolated bacterium capable of forming a spore, (c) a third species of isolated bacterium capable of forming a spore, and (d) a capsule;
wherein the capsule encapsulates the first species, the second species, and the third species;
wherein the first species, the second species, and the third species of bacteria are not identical;
wherein the first species is Clostridium orbiscindens , the second species is Clostridium bolteae , and the third species is Lachnospiraceae bacterium 5_1_57FAA, wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to the sequence set forth in SEQ ID NO: 609;
and wherein a combination of the first species, the second species, and the third species is capable of decreasing and/or inhibiting the growth and/or colonization of at least one type of pathogenic bacteria.
2. The composition of claim 1 , wherein the at least one type of pathogenic bacteria is selected from the group consisting of Yersinia, Vibrio, Treponema, Streptococcus, Staphylococcus, Shigella, Salmonella, Rickettsia, Orientia, Pseudomonas, Providencia, Proteus, Propionibacterium, Neisseria, Mycoplasma, Mycobacterium, Morganella, Listeria, Leptospira, Legionella, Klebsiella, Helicobacter, Haemophilus, Fusobacterium, Francisella, Escherichia, Ehrlichia, Enterococcus, Coxiella, Corynebacterium, Clostridium Chlamydia, Chlamydophila, Campylobacter, Burkholderia, Brucella, Borrelia, Bordetella, Bifidobacterium, Bacillus , multi-drug resistant bacteria, carbapenem-resistant Enterobacteriaceae (CRE), extended spectrum beta-lactam resistant Enterococci (ESBL), and vancomycin-resistant Enterococci (VRE).
3. The composition of claim 1 , wherein the combination of the first species, the second species, and the third species is capable of synergistically inhibiting the growth and/or colonization of the at least one type of pathogenic bacteria.
4. A single dose unit comprising the composition of claim 1 .
5. The composition of claim 2 , wherein the at least one type of pathogenic bacteria is Clostridium difficile.
6. The composition of claim 1 , wherein one or more of the first species, the second species, and the third species are in the form of spores.
7. The composition of claim 1 , wherein the capsule is enterically coated.
8. The composition of claim 1 , which further comprises glycerol.
9. The composition of claim 1 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 98% identical to the sequence set forth in SEQ ID NO: 609.
10. The composition of claim 1 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 99% identical to the sequence set forth in SEQ ID NO: 609.
11. The composition of claim 1 , wherein the Clostridium orbiscindens comprises the 16S rDNA sequence set forth in SEQ ID NO: 609.
12. The composition of claim 1 , wherein the Clostridium bolteae comprises a 16S rDNA sequence that is at least 97% identical to the sequence set forth in SEQ ID NO: 559.
13. The composition of claim 1 , wherein the Clostridium bolteae comprises a 16S rDNA sequence that is at least 98% identical to the sequence set forth in SEQ ID NO: 559.
14. The composition of claim 1 , wherein the Clostridium bolteae comprises a 16S rDNA sequence that is at least 99% identical to the sequence set forth in SEQ ID NO: 559.
15. The composition of claim 1 , wherein the Clostridium bolteae comprises the 16S rDNA sequence set forth in SEQ ID NO: 559.
16. The composition of claim 1 , wherein the Lachnospiraceae bacterium 5_1_57FAA comprises a 16S rDNA sequence that is at least 97% identical to the sequence set forth in SEQ ID NO: 1054.
17. The composition of claim 1 , wherein the Lachnospiraceae bacterium 5_1_57FAA comprises a 16S rDNA sequence that is at least 98% identical to the sequence set forth in SEQ ID NO: 1054.
18. The composition of claim 1 , wherein the Lachnospiraceae bacterium 5_1_57FAA comprises a 16S rDNA sequence that is at least 99% identical to the sequence set forth in SEQ ID NO: 1054.
19. The composition of claim 1 , wherein the Lachnospiraceae bacterium 5_1_57FAA comprises the 16S rDNA sequence set forth in SEQ ID NO: 1054.